Central Pain Syndrome in Survivors of Head and Neck Cancer
Overview
This is a cross-sectional pilot study of head and neck cancer survivors who have completed multi-modal treatment to assess and characterize the presence of distinct pain syndromes.
Full Title of Study: “Characterization of Central Pain Syndrome in Survivors of Head and Neck Cancer”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Diagnostic
- Masking: None (Open Label)
- Study Primary Completion Date: July 21, 2022
Detailed Description
Primary objectives: – To correlate structural and functional MRI signature with one of three pain phenotypes in head and neck cancer survivors: 1) no pain, 2) central pain, and 3) nociceptive pain. – To correlate the presence of chronic systemic symptoms with pain phenotype Exploratory objectives: – DNA, RNA, and plasma will be collected for genomic, transcriptomic, and proteomic studies. Results will be vertically integrated along with the results of clinical studies described within this protocol to identify targets for future correlative studies.
Interventions
- Device: IPC-1000
- Delivers pressure to thumbnail for five seconds at a time
- Device: Magnetic resonance imaging
- Scan of brain using Magnetic resonance imaging
- Other: Correlative Studies
- Administration of questionnaires via computer
Arms, Groups and Cohorts
- Experimental: Response to Pain
- Brain’s response to pain using magnetic resonance imaging (MRI)
Clinical Trial Outcome Measures
Primary Measures
- Magnetic Resonance Imaging (MRI) to Correlate With One of Three Pain Phenotypes 1) no Pain, 2) Central Pain, 3) Nociceptive Pain
- Time Frame: Approximately 8 weeks
- MRI scan of brain to measure response to stimulated pressure to thumbnail
- Magnetic Resonance Imaging (MRI) to Correlate Presence of Chronic Systemic Symptoms With Pain Phenotype
- Time Frame: Approximately 8 weeks
- MRI scan of brain to measure response to stimulated pressure to thumbnail
Participating in This Clinical Trial
Inclusion Criteria
- Patients with histologically proven head and neck cancer – Patients without a diagnosis of head and neck cancer (up to 10 patients, see below) – We anticipate enrolling a total of 75 patients with a history of head and neck cancer who will complete all questionnaires and MRI scanning. We will also recruit up to 10 patients WITHOUT a diagnosis of head and neck cancer to facilitate optimization of the MRI scanning processes. This will allow us to address logistical issues, such as pressure stimulator setup and timing of each scan to be performed. – Completed multi-modality therapy a minimum of 6 weeks prior to study entry. – Willing and able to provide informed consent – All participants must be at least 21 years of age – Able to speak English Exclusion Criteria:
- Patients who are pregnant – Patients who are unable to lie still – Patients who are unable tolerate pressure stimulator – Non-MRI compatible devices such as aneurysm clips, cardiac pacemakers or defibrillators, cochlear implants, hardware, or any other implants – Iron-based tattoos, pieces of metal (bullet, BB, shrapnel) close to or in an important organ (such as the eye), or other non-MRI compatible metal in the body
Gender Eligibility: All
Minimum Age: 21 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Collaborator
- National Cancer Institute (NCI)
- Provider of Information About this Clinical Study
- Principal Investigator: Dianne Lou, Principal Investigator – Vanderbilt-Ingram Cancer Center
- Overall Official(s)
- Dianne Lou, MD, PhD, Principal Investigator, Vanderbilt Medical Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.